{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-053049","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.484407+00:00","generated_at":"2026-05-16T02:19:39.795336+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM","bullets":["European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.","Approved dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg tablets.","MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity.","Indication covers NYHA class II-III obstructive hypertrophic cardiomyopathy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-053049","json":"https://secwatch.observer/filing/0001193125-26-053049.json","markdown":"https://secwatch.observer/filing/0001193125-26-053049.md","text":"https://secwatch.observer/filing/0001193125-26-053049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/0001193125-26-053049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/cytk-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:19:39.795336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-022979","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-05-27T20:01:34+00:00","headline":"FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-022979","json":"https://secwatch.observer/filing/0001140361-26-022979.json","markdown":"https://secwatch.observer/filing/0001140361-26-022979.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/0001140361-26-022979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-065992","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-05-26T11:15:41+00:00","headline":"FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065992","json":"https://secwatch.observer/filing/0001104659-26-065992.json","markdown":"https://secwatch.observer/filing/0001104659-26-065992.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/0001104659-26-065992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064861","ticker":"RGTI","company_name":"Rigetti Computing, Inc.","filed_at":"2026-05-21T11:30:49+00:00","headline":"Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity","event_type":"regulatory","sec_items":["3.02","8.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064861","json":"https://secwatch.observer/filing/0001104659-26-064861.json","markdown":"https://secwatch.observer/filing/0001104659-26-064861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/0001104659-26-064861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/tm2615300d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001651308-26-000012","ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2026-05-15T20:08:07+00:00","headline":"BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-26-000012","json":"https://secwatch.observer/filing/0001651308-26-000012.json","markdown":"https://secwatch.observer/filing/0001651308-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/0001651308-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/bgne-20260513.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-224069","ticker":"AARD","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-05-14T20:15:34+00:00","headline":"FDA places full clinical hold on Aardvark's ARD-101 IND; HERO and OLE trials paused","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224069","json":"https://secwatch.observer/filing/0001193125-26-224069.json","markdown":"https://secwatch.observer/filing/0001193125-26-224069.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526224069/0001193125-26-224069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526224069/ck0001774857-20260514.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-021036","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-05-13T20:01:37+00:00","headline":"BridgeBio submits NDA to FDA for encaleret in ADH1; Phase 3 data shows 76% achieved target calcium levels","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-021036","json":"https://secwatch.observer/filing/0001140361-26-021036.json","markdown":"https://secwatch.observer/filing/0001140361-26-021036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126021036/0001140361-26-021036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126021036/ef20073370_form8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251517","ticker":"LESL","company_name":"Leslie's, Inc.","filed_at":"2026-06-01T20:28:42+00:00","headline":"Leslie's regains Nasdaq compliance for minimum market value of publicly held shares","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251517","json":"https://secwatch.observer/filing/0001193125-26-251517.json","markdown":"https://secwatch.observer/filing/0001193125-26-251517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/0001193125-26-251517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/lesl-20260529.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}